InfoBionic – a digital health company focused on virtual telemetry and cardiac remote patient monitoring – recently announced the initial closing of its Series D financing round to support continued domestic growth and international expansion of its newly FDA-approved MoMe ARC system for virtual telemetry and remote wireless monitoring and detection of cardiac arrhythmias.
The series D funding round includes Security International Investments (SII), Mayo Clinic, and Excel Venture Management participation. At the same time, distinguished existing investors such as Blue Cross Blue Shield of MA (Zaffre Investments), Blue Cross Blue Shield of Kansas, and Safeguard Scientifics remain actively involved.
KEY QUOTES:
“We’re very proud of our role in the evolving transformation of virtual telemetry for remote cardiac monitoring, and we are excited at the prospects of what we can accomplish in this next phase of virtual care.”
“We are pleased by the completion of this latest round, which was based on the strong market traction of our proprietary MoMe Kardia system.”
“Through collaborations with great minds in medicine and technology, we remain committed to doing things better to improve patient outcomes while making it easier and more efficient for the many providers that care for those patients.”
— Stuart Long, CEO of InfoBionic, the leading digital health company that created the MoMe ARC remote cardiac monitoring platform
